<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14865">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01785108</url>
  </required_header>
  <id_info>
    <org_study_id>DIABGAD-1</org_study_id>
    <nct_id>NCT01785108</nct_id>
  </id_info>
  <brief_title>DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen</brief_title>
  <official_title>Pilot Trial to Preserve Residual Insulin Secretion in Children and Adolescents With Recent Onset Type 1 Diabetes by Using GAD-antigen (Diamyd) Therapy in Combination With Vitamin D and Ibuprofen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnny Ludvigsson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Swedish Child Diabetes Foundation (Barndiabetesfonden)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Research Council of South East Sweden (FORSS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ALF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diamyd Therapeutics AB (unrestricted grant)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Linkoeping University</source>
  <oversight_info>
    <authority>Sweden: Medical Products Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study is to

        -  evaluate the safety and influence of treatment with GAD-Alum (Diamyd) combined with
           Vitamin D and Ibuprofen on preservation of residual insulin secretion in recently
           diagnosed Type 1 Diabetes

        -  evaluate how the above mentioned treatments influence the immune system of the subjects
           and interact with any viral infections

        -  evaluate the safety and influence of treatment with double dose of GAD-Alum (Diamyd)
           plus Vitamin D on the immune system, viral infections, and on preservation of residual
           insulin secretion in recently diagnosed Type 1 Diabetes
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in C-peptide (90 minute value and AUC mean 0-120 min) during a Mixed Meal Tolerance Test from baseline to month 6, 15 and 30</measure>
    <time_frame>6 months, 15 months and 30 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a stimulated maximum C-peptide level above 0.2 nmol/L</measure>
    <time_frame>6, 15 and 30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c (HbA1c), change between baseline and subsequent visits</measure>
    <time_frame>6, 15 and 30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exogenous insulin dose per kg body weight and 24  hours, change between baseline and subsequent visits</measure>
    <time_frame>6, 15 and 30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Th2-deviation of cell-mediated immune response seen, e.g. as increased ratio of IL-5, 10, 13 in comparison with IFN-gamma, TNF-alfa, IL-1 beta, IL-17, and increase of T-regulatory cells</measure>
    <time_frame>6, 15 and 30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in inflammatory markers, e.g. TNF-alfa, IL-1 beta, IL-2, IL-17</measure>
    <time_frame>6, 15 and 30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting C-peptide, change between baseline and month 6, 15 and 30</measure>
    <time_frame>6, 15 and 30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>GAD-Alum (Diamyd) 20µg, Vitamin D and Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GAD-Alum (Diamyd) 20 µg given twice with one month interval
Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450
Ibuprofen, 400 mg/day, from Day 1 to Day 90</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GAD-Alum (Diamyd) 20µg and Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GAD-Alum (Diamyd) 20 µg given twice with one month interval
Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GAD-Alum (Diamyd) 20 µg x 2 and Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GAD-Alum (Diamyd) 20 µg X 2 given twice with one month interval
Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GAD-Alum (Diamyd) 20 µg</intervention_name>
    <arm_group_label>GAD-Alum (Diamyd) 20µg, Vitamin D and Ibuprofen</arm_group_label>
    <arm_group_label>GAD-Alum (Diamyd) 20µg and Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GAD-Alum (Diamyd) 20 µg X 2</intervention_name>
    <arm_group_label>GAD-Alum (Diamyd) 20 µg x 2 and Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <arm_group_label>GAD-Alum (Diamyd) 20µg, Vitamin D and Ibuprofen</arm_group_label>
    <arm_group_label>GAD-Alum (Diamyd) 20µg and Vitamin D</arm_group_label>
    <arm_group_label>GAD-Alum (Diamyd) 20 µg x 2 and Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <arm_group_label>GAD-Alum (Diamyd) 20µg, Vitamin D and Ibuprofen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Male and female patients between 10 and 18 years of age

          -  Insulin dependent Type 1 Diabetes mellitus diagnosed within the previous 4 months at
             time of screening

          -  Fasting C-peptide level at time of screening above or equal to 0.12 nmol/L

          -  Elevated GAD65 antibodies (GADA) at time of screening

        Main Exclusion Criteria:

          -  Treatment with immunosuppressants, continuous anti-inflammatory drug, Vitamin D or
             any anti-diabetic medications other than insulin

          -  A history of certain diseases or conditions (e.g. anemia, HIV, epilepsy, head trauma,
             neurological diseases or cerebrovascular accident, alcohol or drug abuse etc)

          -  Treatment with any vaccine within 4 months prior to first planned administration of
             GAD-Alum/placebo or planned treatment with vaccine up to 4 months after the last
             injections with GAD-Alum/Placebo, including influenza vaccines

          -  Participation in other clinical trials with a new chemical entity within the previous
             3 months

          -  Pregnancy or planned pregnancy within 1 year after the last GAD-Alum/placebo  dose

          -  Presence of associated serious disease or condition which in the opinion of the
             investigator makes the patient non-eligible for the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnny Ludvigsson, MD,PhD,Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linköping University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johnny Ludvigsson</last_name>
    <email>johnny.ludvigsson@liu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosaura Casas</last_name>
    <email>rosaura.casas@liu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Halmstad Hospital</name>
      <address>
        <city>Halmstad</city>
        <zip>SE-301 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Torben Ek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Astrid Lindgren Children's Hospital - Huddinge</name>
      <address>
        <city>Huddinge</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Torun Torbjornsdotter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kalmar Hospital</name>
      <address>
        <city>Kalmar</city>
        <zip>SE-391 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Göran Lundström, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linköping University</name>
      <address>
        <city>Linköping</city>
        <zip>SE-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johnny Ludvigsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Annelie Carlsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital, UMAS</name>
      <address>
        <city>Malmö</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Helena Larsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Astrid Lindgren Children's Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eva Örtqvist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sachsska, Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Björn Rathsman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uddevalla Hospital</name>
      <address>
        <city>Uddevalla</city>
        <zip>SE-451 80</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ragnar Hanås, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <zip>SE-701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jan Åman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 24, 2013</lastchanged_date>
  <firstreceived_date>February 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Linkoeping University</investigator_affiliation>
    <investigator_full_name>Johnny Ludvigsson</investigator_full_name>
    <investigator_title>MD, PhD, Professor</investigator_title>
  </responsible_party>
  <keyword>Diamyd</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Juvenile Diabetes</keyword>
  <keyword>Diabetes type 1</keyword>
  <keyword>Autoimmune Diabetes</keyword>
  <keyword>Insulin dependent Diabetes</keyword>
  <keyword>Type 1 diabetes</keyword>
  <keyword>Type 1 diabetes mellitus</keyword>
  <keyword>rhGAD65</keyword>
  <keyword>GAD</keyword>
  <keyword>GAD65</keyword>
  <keyword>GAD-alum</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Diabetes Mellitus, Type 1</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Ibuprofen</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Aluminum sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
